Srini Ramanathan

Chief Development Officer at Roivant Sciences

Srini Ramanathan, Ph.D., joins us from Horizon Therapeutics, where he was Senior Vice President of Research and Development Sciences, with portfolio oversight of discovery, preclinical research and several development functions; he also oversaw scientific due diligence for business development evaluations. He has worked in the biotechnology industry over 20 years and has been involved in drug approvals across ophthalmology, oncology and virology. Before joining Horizon, Ramanathan served as senior project leader at AbbVie, overseeing the development of multiple immunology programs for rheumatology and gastrointestinal indications. Prior to AbbVie, he served as global head of clinical pharmacology at Gilead Sciences with responsibilities for portfolio programs across all therapeutic areas. Ramanathan earned his Master of Science in pharmaceutics from Duquesne University and his doctorate in pharmaceutics from Rutgers University.

Links

Previous companies

Gilead Sciences logo
AbbVie logo

Peers

View in org chart

Timeline

  • Chief Development Officer

    Current role

View in org chart